Evidence map›Paper›PMID 38657185›Full record

ArticleNeurology(R) neuroimmunology & neuroinflammation2024

Phenotypic Insights Into Anti-IgLON5 Disease in IgLON5-Deficient Mice.

Sin Yi Lee, Hirotaka Shoji, Aki Shimozawa, Hirofumi Aoyagi, Yoshiaki Sato, Kazuya Tsumagari, Mika Terumitsu, Haruhiko Motegi, Kensuke Okada, Koji Sekiguchi and 4 more

Open access · goldAbstract read
In one paragraph

Article in Neurology(R) neuroimmunology & neuroinflammation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Anti-IgLON5 Disease 10 Years Later: What We Know and What We Do Not Know.Neurology(R) neuroimmunology & neuroinflammation · 2025
    Review
  5. Recent advances in autoimmune encephalitis.Arquivos de neuro-psiquiatria · 2024
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Sin Yi LeeFrom the Department of Neurology (S.Y.L., H.M., K.O., K.S., J.N.), Keio University School of Medicine, Tokyo; Division of Systems Medical Science (H.S., T.M.), Center for Medical Science, Fujita Health University, Toyoake; Eisai-Keio Innovation Laboratory for Dementia (A.S., H.A., Y.S., M.T., J.K.), Human Biology Integration, DHBL, Eisai Co., Ltd., Shinjuku-ku; Proteome Homeostasis Research Unit (K.T.), RIKEN Center for Integrative Medical Sciences, Yokohama; Department of Neurology (H.M.), The Jikei University School of Medicine; and Department of Physiology/Memory Center (D.I.), Keio University School of Medicine, Tokyo, Japan.
Hirotaka ShojiFrom the Department of Neurology (S.Y.L., H.M., K.O., K.S., J.N.), Keio University School of Medicine, Tokyo; Division of Systems Medical Science (H.S., T.M.), Center for Medical Science, Fujita Health University, Toyoake; Eisai-Keio Innovation Laboratory for Dementia (A.S., H.A., Y.S., M.T., J.K.), Human Biology Integration, DHBL, Eisai Co., Ltd., Shinjuku-ku; Proteome Homeostasis Research Unit (K.T.), RIKEN Center for Integrative Medical Sciences, Yokohama; Department of Neurology (H.M.), The Jikei University School of Medicine; and Department of Physiology/Memory Center (D.I.), Keio University School of Medicine, Tokyo, Japan.
Aki ShimozawaFrom the Department of Neurology (S.Y.L., H.M., K.O., K.S., J.N.), Keio University School of Medicine, Tokyo; Division of Systems Medical Science (H.S., T.M.), Center for Medical Science, Fujita Health University, Toyoake; Eisai-Keio Innovation Laboratory for Dementia (A.S., H.A., Y.S., M.T., J.K.), Human Biology Integration, DHBL, Eisai Co., Ltd., Shinjuku-ku; Proteome Homeostasis Research Unit (K.T.), RIKEN Center for Integrative Medical Sciences, Yokohama; Department of Neurology (H.M.), The Jikei University School of Medicine; and Department of Physiology/Memory Center (D.I.), Keio University School of Medicine, Tokyo, Japan.
Hirofumi AoyagiFrom the Department of Neurology (S.Y.L., H.M., K.O., K.S., J.N.), Keio University School of Medicine, Tokyo; Division of Systems Medical Science (H.S., T.M.), Center for Medical Science, Fujita Health University, Toyoake; Eisai-Keio Innovation Laboratory for Dementia (A.S., H.A., Y.S., M.T., J.K.), Human Biology Integration, DHBL, Eisai Co., Ltd., Shinjuku-ku; Proteome Homeostasis Research Unit (K.T.), RIKEN Center for Integrative Medical Sciences, Yokohama; Department of Neurology (H.M.), The Jikei University School of Medicine; and Department of Physiology/Memory Center (D.I.), Keio University School of Medicine, Tokyo, Japan.
Yoshiaki SatoFrom the Department of Neurology (S.Y.L., H.M., K.O., K.S., J.N.), Keio University School of Medicine, Tokyo; Division of Systems Medical Science (H.S., T.M.), Center for Medical Science, Fujita Health University, Toyoake; Eisai-Keio Innovation Laboratory for Dementia (A.S., H.A., Y.S., M.T., J.K.), Human Biology Integration, DHBL, Eisai Co., Ltd., Shinjuku-ku; Proteome Homeostasis Research Unit (K.T.), RIKEN Center for Integrative Medical Sciences, Yokohama; Department of Neurology (H.M.), The Jikei University School of Medicine; and Department of Physiology/Memory Center (D.I.), Keio University School of Medicine, Tokyo, Japan.
Kazuya TsumagariFrom the Department of Neurology (S.Y.L., H.M., K.O., K.S., J.N.), Keio University School of Medicine, Tokyo; Division of Systems Medical Science (H.S., T.M.), Center for Medical Science, Fujita Health University, Toyoake; Eisai-Keio Innovation Laboratory for Dementia (A.S., H.A., Y.S., M.T., J.K.), Human Biology Integration, DHBL, Eisai Co., Ltd., Shinjuku-ku; Proteome Homeostasis Research Unit (K.T.), RIKEN Center for Integrative Medical Sciences, Yokohama; Department of Neurology (H.M.), The Jikei University School of Medicine; and Department of Physiology/Memory Center (D.I.), Keio University School of Medicine, Tokyo, Japan.
Mika TerumitsuFrom the Department of Neurology (S.Y.L., H.M., K.O., K.S., J.N.), Keio University School of Medicine, Tokyo; Division of Systems Medical Science (H.S., T.M.), Center for Medical Science, Fujita Health University, Toyoake; Eisai-Keio Innovation Laboratory for Dementia (A.S., H.A., Y.S., M.T., J.K.), Human Biology Integration, DHBL, Eisai Co., Ltd., Shinjuku-ku; Proteome Homeostasis Research Unit (K.T.), RIKEN Center for Integrative Medical Sciences, Yokohama; Department of Neurology (H.M.), The Jikei University School of Medicine; and Department of Physiology/Memory Center (D.I.), Keio University School of Medicine, Tokyo, Japan.
Haruhiko MotegiFrom the Department of Neurology (S.Y.L., H.M., K.O., K.S., J.N.), Keio University School of Medicine, Tokyo; Division of Systems Medical Science (H.S., T.M.), Center for Medical Science, Fujita Health University, Toyoake; Eisai-Keio Innovation Laboratory for Dementia (A.S., H.A., Y.S., M.T., J.K.), Human Biology Integration, DHBL, Eisai Co., Ltd., Shinjuku-ku; Proteome Homeostasis Research Unit (K.T.), RIKEN Center for Integrative Medical Sciences, Yokohama; Department of Neurology (H.M.), The Jikei University School of Medicine; and Department of Physiology/Memory Center (D.I.), Keio University School of Medicine, Tokyo, Japan.ORCID 0009-0003-2035-5095
Kensuke OkadaFrom the Department of Neurology (S.Y.L., H.M., K.O., K.S., J.N.), Keio University School of Medicine, Tokyo; Division of Systems Medical Science (H.S., T.M.), Center for Medical Science, Fujita Health University, Toyoake; Eisai-Keio Innovation Laboratory for Dementia (A.S., H.A., Y.S., M.T., J.K.), Human Biology Integration, DHBL, Eisai Co., Ltd., Shinjuku-ku; Proteome Homeostasis Research Unit (K.T.), RIKEN Center for Integrative Medical Sciences, Yokohama; Department of Neurology (H.M.), The Jikei University School of Medicine; and Department of Physiology/Memory Center (D.I.), Keio University School of Medicine, Tokyo, Japan.
Koji SekiguchiFrom the Department of Neurology (S.Y.L., H.M., K.O., K.S., J.N.), Keio University School of Medicine, Tokyo; Division of Systems Medical Science (H.S., T.M.), Center for Medical Science, Fujita Health University, Toyoake; Eisai-Keio Innovation Laboratory for Dementia (A.S., H.A., Y.S., M.T., J.K.), Human Biology Integration, DHBL, Eisai Co., Ltd., Shinjuku-ku; Proteome Homeostasis Research Unit (K.T.), RIKEN Center for Integrative Medical Sciences, Yokohama; Department of Neurology (H.M.), The Jikei University School of Medicine; and Department of Physiology/Memory Center (D.I.), Keio University School of Medicine, Tokyo, Japan.
Junro KuromitsuFrom the Department of Neurology (S.Y.L., H.M., K.O., K.S., J.N.), Keio University School of Medicine, Tokyo; Division of Systems Medical Science (H.S., T.M.), Center for Medical Science, Fujita Health University, Toyoake; Eisai-Keio Innovation Laboratory for Dementia (A.S., H.A., Y.S., M.T., J.K.), Human Biology Integration, DHBL, Eisai Co., Ltd., Shinjuku-ku; Proteome Homeostasis Research Unit (K.T.), RIKEN Center for Integrative Medical Sciences, Yokohama; Department of Neurology (H.M.), The Jikei University School of Medicine; and Department of Physiology/Memory Center (D.I.), Keio University School of Medicine, Tokyo, Japan.
Jin NakaharaFrom the Department of Neurology (S.Y.L., H.M., K.O., K.S., J.N.), Keio University School of Medicine, Tokyo; Division of Systems Medical Science (H.S., T.M.), Center for Medical Science, Fujita Health University, Toyoake; Eisai-Keio Innovation Laboratory for Dementia (A.S., H.A., Y.S., M.T., J.K.), Human Biology Integration, DHBL, Eisai Co., Ltd., Shinjuku-ku; Proteome Homeostasis Research Unit (K.T.), RIKEN Center for Integrative Medical Sciences, Yokohama; Department of Neurology (H.M.), The Jikei University School of Medicine; and Department of Physiology/Memory Center (D.I.), Keio University School of Medicine, Tokyo, Japan.
Tsuyoshi MiyakawaFrom the Department of Neurology (S.Y.L., H.M., K.O., K.S., J.N.), Keio University School of Medicine, Tokyo; Division of Systems Medical Science (H.S., T.M.), Center for Medical Science, Fujita Health University, Toyoake; Eisai-Keio Innovation Laboratory for Dementia (A.S., H.A., Y.S., M.T., J.K.), Human Biology Integration, DHBL, Eisai Co., Ltd., Shinjuku-ku; Proteome Homeostasis Research Unit (K.T.), RIKEN Center for Integrative Medical Sciences, Yokohama; Department of Neurology (H.M.), The Jikei University School of Medicine; and Department of Physiology/Memory Center (D.I.), Keio University School of Medicine, Tokyo, Japan.
Daisuke ItoFrom the Department of Neurology (S.Y.L., H.M., K.O., K.S., J.N.), Keio University School of Medicine, Tokyo; Division of Systems Medical Science (H.S., T.M.), Center for Medical Science, Fujita Health University, Toyoake; Eisai-Keio Innovation Laboratory for Dementia (A.S., H.A., Y.S., M.T., J.K.), Human Biology Integration, DHBL, Eisai Co., Ltd., Shinjuku-ku; Proteome Homeostasis Research Unit (K.T.), RIKEN Center for Integrative Medical Sciences, Yokohama; Department of Neurology (H.M.), The Jikei University School of Medicine; and Department of Physiology/Memory Center (D.I.), Keio University School of Medicine, Tokyo, Japan.ORCID 0000-0002-4740-1675
Eisai (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesAnti-IgLON5 disease is an autoimmune neurodegenerative disorder characterized by various phenotypes, notably sleep and movement disorders and tau pathology. Although the disease is known to be associated with the neuronal cell adhesion protein IgLON5, the physiologic function of IgLON5 remains elusive. There are conflicting views on whether autoantibodies cause loss of function, activation of IgLON5, or inflammation-associated neuronal damage, ultimately leading to the disease. We generated IgLON5 knockout (-/-) mice to investigate the functions of IgLON5 and elucidate the pathomechanism of anti-IgLON5 disease.

methodsIgLON5 knockout (-/-) mice underwent behavioral tests investigating motor function, psychiatric function (notably anxiety and depression), social and exploratory behaviors, spatial learning and memory, and sensory perception. Histologic analysis was conducted to investigate tau aggregation in mice with tauopathy.

resultsIgLON5 DISCUSSION: These results suggest that IgLON5 is associated with activity, anxiety, motor ability, and contextual fear memory. Comparing the various phenotypes of anti-IgLON5 disease, anti-IgLON5 disease might partially be associated with loss of function of IgLON5; however, other phenotypes, such as sleep disorders and tau aggregation, can be caused by gain of function of IgLON5 and/or neuronal damage due to inflammation. Further studies are needed to elucidate the role of IgLON5 in the pathogenesis of anti-IgLON5 diseases.

Indexed as

Cell Adhesion Molecules, NeuronalMice, KnockoutPhenotypeAnimalsAnxietyAutoantibodiesBehavior, AnimalDisease Models, AnimalHumansMaleMiceMice, Inbred C57BLTauopathiesAutoantibodiesCell Adhesion Molecules, Neuronal

Identifiers

PMID38657185
PMCPMC11087031
OpenAlexW4395116358

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.